Stockscreener 앱 받기
6.99
4.12%
-0.30
시간 외 거래:
6.99
전일 마감가:
$7.29
열려 있는:
$7.21
하루 거래량:
11,518
Relative Volume:
0.17
시가총액:
$9.22M
수익:
$35.75M
순이익/손실:
$11.57M
주가수익비율:
-1.8361
EPS:
-3.8069
순현금흐름:
$-26.25M
1주 성능:
-11.41%
1개월 성능:
-20.43%
6개월 성능:
-40.96%
1년 성능:
-16.16%
1일 변동 폭
$6.99
$7.3704
1주일 범위
$6.70
$7.75
52주 변동 폭
$6.70
$82.00
레드힐 바이오파마 ADR Stock (RDHL) Company Profile
명칭
Redhill Biopharma Ltd Adr
전화
-
주소
-
RDHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RDHL | 6.99 | 9.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
레드힐 바이오파마 ADR Stock (RDHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-08-31 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2020-09-11 | 개시 | BTIG Research | Buy |
| 2019-07-12 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 개시 | Nomura | Buy |
| 2017-10-06 | 개시 | Seaport Global Securities | Buy |
| 2017-10-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-24 | 재확인 | FBR & Co. | Outperform |
| 2016-07-27 | 재확인 | FBR Capital | Outperform |
| 2015-09-29 | 개시 | Nomura | Buy |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2015-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-15 | 재확인 | ROTH Capital | Buy |
모두보기
레드힐 바이오파마 ADR 주식(RDHL)의 최신 뉴스
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - StockTitan
Taking on analysts’ expectations and winning: Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com India
Balance Sheet Breakdown: Redhill Biopharma Ltd. ADR (RDHL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Redhill Biopharma Ltd. ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
Its Stock Has Paid Off Big Time For Teck Resources Ltd - SETE News
Are Smart Investors Making the Right Decision? Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Check Out Aveanna Healthcare Holdings Inc (AVAH)’s Trade Data Rather Than the Analysts’ Views - SETE News
RDHL’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Can you now get a good deal on Redhill Biopharma Ltd. ADR’s shares? - US Post News
Is ThredUp Inc (TDUP) positioned for future growth? - SETE News
A look into Redhill Biopharma Ltd. ADR (RDHL)’s deeper side - SETE News
Immuneering Corp (IMRX) expanding its growth trajectory ahead - SETE News
Cipher Mining Inc (CIFR) is looking forward to a strong quarter - SETE News
Nothing is Better Than Hut 8 Corp (HUT) stock at the moment - SETE News
Analytical Overview: Redhill Biopharma Ltd. ADR (RDHL)’s Ratios Tell a Financial Story - The Dwinnex
Redhill Biopharma Ltd. ADR [RDHL] Revenue clocked in at $35.52 million, down -68.49% YTD: What’s Next? - The DBT News
Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Should investors be concerned about RDHL’s high price-to-sales ratio? - US Post News
Exact Sciences Corp. (EXAS) Stock: A Year of Decreases and Increases - The InvestChronicle
New Outlook On Alibaba Group Holding Ltd ADR - Stocks Register
Baker Hughes Co (NASDAQ: BKR) Up 1.26%: This Is What Analysts Are Now Forecasting - Stocks Register
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination - US Post News
Redhill Biopharma Ltd. ADR (RDHL) Stock: A Year of Market Fluctuations - The InvestChronicle
Ratio Examination: Redhill Biopharma Ltd. ADR (RDHL)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com India
Redhill Biopharma Ltd. ADR (RDHL)'s stock performance: a year in review – US Post News - US Post News
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation - Yahoo Lifestyle UK
Ratio Analysis: Unpacking Redhill Biopharma Ltd. ADR (RDHL)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Should investors be concerned about Redhill Biopharma Ltd. ADR (RDHL)? – US Post News - US Post News
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study - Yahoo News UK
Emerging Technologies in the Proton Pump Inhibitors Market to Hit US$ 3.5 Billion by 2031 - openPR
The Psychology of Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: Understanding Market Sentiment - The InvestChronicle
Proton Pump Inhibitors Market In-depth Analysis, Rising Business Opportunities And Estimated Forecast Till 2031 ... - openPR
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination – US Post News - US Post News
RedHill Biopharma secures $1.25 million in direct offering By Investing.com - Investing.com
KALA Stock Quote Price and Forecast - CNN
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
레드힐 바이오파마 ADR (RDHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.15%
자본화:
|
볼륨(24시간):